Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01575522 · ClinicalTrials.gov registry record · Phase 2
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
A Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT01575522 is a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 22 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01575522, a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well tivantinib works in treating patients with recurrent or metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tivantinib
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute Faulkner Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01575522
The ClinicalTrials.gov registry entry for NCT01575522 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (67% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01575522 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01575522 about?
NCT01575522 is a clinical study titled "Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer". This phase II trial studies how well tivantinib works in treating patients with recurrent or metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01575522?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2012-03. Estimated completion is 2013-07.
What conditions does trial NCT01575522 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Carcinoma, HER2/Neu Negative, Triple-Negative Breast Carcinoma, Estrogen Receptor Negative.
What interventions are being tested in trial NCT01575522?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tivantinib (DRUG).
Who is sponsoring clinical trial NCT01575522?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01575522 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
COMPLETED · Phase 2
-
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.